KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth

Background Gliomas are one of the most lethal cancers in the human central nervous system. Despite clinical treatment advancements, the prognosis of patients with glioma remains poor. KDM2B is a histone lysine demethylase, which has been observed in multiple tumors. But the concrete role of KDM2B in gliomas remains to be further illustrated. Methods The KDM2B expression in gliomas was detected with immunohistochemistry and Western blot assay. Furthermore, knockdown of KDM2B in U87 and U251 glioma cell lines, the proliferation capacity was evaluated by cell viability assay, colon formation assay and flow cytometry in vitro. Western blot assay was used to analyze the p21, EZH2 and cyclinD1 changes followed by knockdown of KDM2B. Results KDM2B was upregulated in tissues of glioma patients, and the expression was correlated to cancer progression. Downregulation of KDM2B in U87 and U251 glioma cell lines inhibited cell proliferation and arrested cell cycle in G0/G1 phase. In addition, silencing KDM2B promoted the upregulation of p21 while reduced the expression of EZH2 and cyclinD1. Conclusion Taken together, our results revealed that KDM2B might influence gliomas growth and act as a novel therapeutic target for glioma patients.

• Publication year

  2018

• Venue

  OncoTargets and Therapy

• Publication date

  2018-01-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2147/OTT.S149833PMID 29386904PMCID 5764301
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target

  2017cited by this paper
• Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells.

  2017cited by this paper
• KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL

  2017cited by this paper
• Analysis of EZH2: micro-RNA network in low and high grade astrocytic tumors

  2016cited by this paper
• EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features

  2016cited by this paper
• EZH2 overexpression is associated with poor prognosis in patients with glioma

  2016cited by this paper
• The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.

  2016cited by this paper
• MicroRNAs and cell cycle of malignant glioma

  2016cited by this paper
• Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.

  2015cited by this paper
• Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.

  2015cited by this paper
• EZH2 Protects Glioma Stem Cells from Radiation-Induced Cell Death in a MELK/FOXM1-Dependent Manner

  2015cited by this paper
• Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2.

  2015cited by this paper
• MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2.

  2015cited by this paper
• A systematic study of the cellular metabolic regulation of Jhdm1b in tumor cells.

  2015cited by this paper
• Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential

  2015cited by this paper
• EZH2 expression is a prognostic factor in childhood intracranial ependymoma: A Canadian Pediatric Brain Tumor Consortium study

  2015cited by this paper
• NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells.

  2014cited by this paper
• The KDM2B- Let-7b -EZH2 Axis in Myelodysplastic Syndromes as a Target for Combined Epigenetic Therapy

  2014cited by this paper
• Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells

  2014cited by this paper
• High-grade gliomas: reality and hopes

  2014cited by this paper
• Overexpression of enhancer of zeste human homolog 2 (EZH2) gene in human cytomegalovirus positive glioblastoma multiforme tissues

  2014cited by this paper
• EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial–mesenchymal transition

  2014cited by this paper
• Inhibition of Enhancer of Zeste Homolog 2 (EZH2) Expression Is Associated With Decreased Tumor Cell Proliferation, Migration, and Invasion in Endometrial Cancer Cell Lines

  2013cited by this paper
• Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.

  2013influential reference
• KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.

  2013cited by this paper
• Polycomb group proteins and their roles in regulating stem cell development.

  2012cited by this paper
• KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.

  2011cited by this paper
• The role of EZH2 in tumour progression

  2011cited by this paper
• Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2

  2011cited by this paper
• Enhancer of Zeste 2 (EZH2) is up‐regulated in malignant gliomas and in glioma stem‐like cells

  2011cited by this paper
• Lysine-specific Demethylase 2B (KDM2B)-let-7-Enhancer of Zester Homolog 2 (EZH2) Pathway Regulates Cell Cycle Progression and Senescence in Primary Cells*

  2011cited by this paper
• Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma

  2011cited by this paper
• FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway.

  2011cited by this paper
• miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis

  2010cited by this paper
• Ndy1/KDM2B immortalizes mouse embryonic fibroblasts by repressing the Ink4a/Arf locus

  2009cited by this paper
• EZH2 is essential for glioblastoma cancer stem cell maintenance.

  2009cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• Members of a family of JmjC domain-containing oncoproteins immortalize embryonic fibroblasts via a JmjC domain-dependent process

  2008cited by this paper
• Chromatin modifications and their function.

  2007cited by this paper
• Histone demethylation by a family of JmjC domain-containing proteins

  2006cited by this paper
• The diverse functions of histone lysine methylation

  2005cited by this paper
• Adenosine Monophosphate-Activated Protein Kinase Suppresses Vascular Smooth Muscle Cell Proliferation Through the Inhibition of Cell Cycle Progression

  2005cited by this paper
• Inhibition of cell cycle progression by penta-acetyl geniposide in rat C6 glioma cells.

  2004cited by this paper
• Cost of migration: invasion of malignant gliomas and implications for treatment.

  2003cited by this paper
• Chromatin Modifications and Their Function

  year unknowncited by this paper

• Deciphering the dose-dependent effects of thymoquinone on cellular proliferation and transcriptomic changes in A172 glioblastoma cells

  2025cites this paper
• STIM1, ORAI1, and KDM2B in circulating tumor cells (CTCs) isolated from prostate cancer patients

  2024cites this paper
• A scoping review regarding reproductive capacity modulation based on alpha-ketoglutarate supplementation

  2024cites this paper
• Transforming Agents: The Power of Structural Modifications in Glioblastoma Multiforme Therapy.

  2024cites this paper
• 2-oxoglutarate-dependent Dioxygenases (2-OGDDs) as Oxygen Sensors: Their Importance in Health and Disease.

  2024cites this paper
• Epigenetic Modifiers: Exploring the Roles of Histone Methyltransferases and Demethylases in Cancer and Neurodegeneration

  2024cites this paper
• Targeting epigenetic mechanisms of resistance to chemotherapy in gliomas.

  2024cites this paper
• Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4

  2023cites this paper
• Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4.

  2023cites this paper
• KDM2B mediates the Wnt/β-catenin pathway through transcriptional activation of PKMYT1 via microRNA-let-7b-5p/EZH2 to affect the development of non-small cell lung cancer.

  2022cites this paper
• Latest updates on cellular and molecular biomarkers of gliomas

  2022cites this paper
• Histone Methylases and Demethylases Regulating Antagonistic Methyl Marks: Changes Occurring in Cancer

  2022cites this paper
• The expression of histone lysine demethylase 2B in canine hemangiosarcoma is associated with disease progression.

  2021cites this paper
• The Role of KDM2B and EZH2 in Regulating the Stemness in Colorectal Cancer Through the PI3K/AKT Pathway

  2021cites this paper
• Genome-wide screens uncover KDM2B as a modifier of protein binding to heparan sulfate

  2021cites this paper
• Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers

  2021cites this paper
• The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma

  2021cites this paper
• Co-overexpression of RIOK1 and AKT1 as a prognostic risk factor in glioma

  2021cites this paper
• USP38 protein alleviates neuroinflammation of cerebral ischemia–reperfusion injury via KDM5B expression

  2021cites this paper
• Pleiotropic effects of alpha-ketoglutarate as a potential anti-ageing agent.

  2020cites this paper
• Targeting post-translational histone modifying enzymes in glioblastoma.

  2020cites this paper
• KDM2B Silencing Elicits a Paracrine Mechanism Which Destabilizes SLUG, Promoting Differentiation of Basal-Like Breast Cancer Cells

  2020cites this paper
• CBP‐triggered KDM2B acetylation accelerates the carcinogenesis of colon cancer

  2020cites this paper
• Systems Biology Approach to Identify Novel Genomic Determinants for Pancreatic Cancer Pathogenesis

  2019cites this paper
• A yeast phenomic model for the influence of Warburg metabolism on genetic buffering of doxorubicin

  2019cites this paper